R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

Leukemia

Volumn 24, Issue 3, 2010, Pages 652-654

  Tonino, S H ^a   Van Gelder, M ^b   Eldering, E ^a   Van Oers, M H ^a   Kater, A P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; OFATUMUMAB; PREDNISONE; RASBURICASE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI PNEUMONIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LETTER; LYMPHADENOPATHY; MALE; MAXILLA SINUSITIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINUSITIS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 77949424740     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.240     Document Type: Letter

References (8)

1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
2. Tam CS, Wierda WG, O'Brien S, Lerner S, Khouri IF, Kantarjian HM, et al. Life after fludarabine, cyclophosphamide, & rituximab (FCR)Fthe clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR. Blood 2008; 112: 727.
3. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537-543.
4. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocy-tic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108: 4187-4193.
5. Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A, et al. High-risk fludarabine-pretreated B-cell chronic lymphocytic Leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Med Oncol 2006; 23: 359-368.
6. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine- refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 196-203.
7. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824-2836.
8. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hahlen K, van Wering ER. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995; 19: 175-181.